Effectiveness of Premedication on the Success Rate of Inferior Alveolar Nerve Block

• Status: Recruiting
• Trial end date: 2022-01-15
• Target enrollment: 0
• Participant gender: All

Summary

Purpose: The aim of this prospective, double-blind, randomized controlled trial is to compare the effect of oral premedication of dexamethasone, ketorolac, meloxicam, ibuprofen or placebo on the success of inferior alveolar nerve blocks (IANB) of mandibular posterior teeth in patients experiencing symptomatic irreversible pulpitis. Methods: The trial will include five study groups, each consists of 50 patients who exhibits symptomatic irreversible pulpitis of a mandibular first or second molar. The patients will receive identically appearing capsules containing either dexamethasone 0.5 mg, ketorolac 10 mg, meloxicam 7.5 mg, ibuprofen 600 mg, or placebo by mouth 60 minutes before the administration of an IANB. Endodontic access will begin 15 minutes after completion of the IANB. The IANB success is defined as no or mild pain (Heft Parker visual analog scale recordings) on pulpal access or instrumentation.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alfarabi Colleges
• Treatments: Dexamethasone; Ibuprofen; Ketorolac; Meloxicam

Criteria

Inclusion Criteria:

• active pain in a mandibular molar first or/and the second molar

• prolonged response to cold testing

• absence of any periapical radiolucency on periapical radiographs

• vital coronal pulp on access opening

• able to give informed consent

Exclusion Criteria:

• less than 18 years old

• history of serious medical problems

• used central nervous system depressants or any analgesic medication within the previous 6 hours

• pregnancy

• inability to give informed consent